Quantumzyme Announces Strategic Rebranding and Planned 4-for-1 Stock Split

Quantumzyme Corp. has announced continued progress on strategic corporate initiatives designed to position the company for its next development phase, including a planned four-for-one forward stock split and advancement of a previously announced corporate name and trading symbol change. The company confirmed its Board of Directors has authorized the 4-for-1 forward stock split of its issued and outstanding common stock, intended to enhance the company's public market profile by recalibrating its capital structure to facilitate greater flexibility in share structure, support administrative efficiency in trading, and align the public share profile with the company's current development stage.

The forward split will be submitted for processing only after completion of the pending corporate name and trading symbol change. As previously disclosed, Quantumzyme Corp. is now in final stages of completing a corporate name change to Quantum Genesis AI Corp., reflecting the company's strategic focus on advancing enzyme innovation through artificial intelligence, computational modeling, and data-driven research. The company anticipates the name and corresponding trading symbol change will be completed in the near term, with immediate submission of the forward stock split to the Financial Industry Regulatory Authority following effectiveness.

Naveen Kulkarni, President of Quantumzyme Corp., stated that the planned corporate rebranding and capital structure initiatives are intended to better align the company's public market profile with its long-term strategic direction. Completing the name and symbol change first establishes a clear foundation, and subject to regulatory review, the proposed forward stock split is designed to support a more efficient and accessible public share structure as the company continues executing its technology and operational roadmap. If approved, the forward stock split will increase the number of outstanding shares of common stock while proportionally adjusting the per-share trading price, potentially providing several benefits including increased flexibility to support future corporate initiatives.

The company emphasizes the forward split is not intended to change the overall market capitalization and will not affect proportional ownership interests of existing shareholders, except for minor adjustments that may result from treatment of fractional shares according to customary transfer agent procedures. The planned forward stock split remains subject to regulatory review and approval, with no assurance regarding timing or completion. The company expects to provide additional updates regarding effectiveness of the corporate name and symbol change, as well as timing and status of the forward stock split submission and review process, through subsequent public disclosures. For more information and updates, please visit www.quantumzymecorp.com and the company's profile at www.otcmarkets.com/stock/QTZM.